U.S. health regulators approved a pill from Bristol-Myers Squibb Co. that is the first to treat people with the most common genetic heart disease.
The Food and Drug Administration cleared the drug on for people showing symptoms of the condition, which can lead to blood clots, strokes and in rare cases, death, Bristol said Thursday.
To Read the Full Story
This post first appeared on wsj.com
